ANDA 207365, held by Chartwell Rx. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 207365 (Triamcinolone Acetonide), held by Chartwell Rx, was first approved by FDA on Oct 12, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 12, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% ยท ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
